ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.

Sarah A Weiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.